Title of article
Idarucizumab in High-risk Thoracic Surgery
Author/Authors
López-Vilella, R. Heart Failure and Transplantation Unit- Cardiology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain , Sánchez, J. Sanz Heart Failure and Transplantation Unit- Cardiology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain , Lázaro, I. Sánchez Heart Failure and Transplantation Unit- Cardiology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain , Sule, E. Marques Physiotherapy Department- University of Valencia, Valencia, Spain , Soriano, J. Rueda Adult Congenital Heart Disease Unit- Cardiology Department- Hospital Universitario y Politécnico La Fe, Valencia, Spain , Bonet, L. Almenar Heart Failure and Transplantation Unit- Cardiology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Pages
4
From page
97
To page
100
Abstract
Direct oral anticoagulants have suggested a favorable profile compared with vitamin K antagonists.
However, the lack of treatment to reverse the effect of direct oral anticoagulants has
limited its use in some patients who require rapid reversal of anticoagulation, as those included
in the transplant waiting list. Idarucizumab is a recently approved drug to reverse the anticoagulant
effect of dabigatran. However, the clinical experience when using this drug is scarce.
Herein, we present a clinical case on anticoagulation reversal with idarucizumab to perform
heart and lung transplantation in a patient with Eisenmenger syndrome.
Keywords
Idarucizumab , Heart-lung transplantation , Anticoagulants
Journal title
Astroparticle Physics
Serial Year
2018
Record number
2481558
Link To Document